Acelyrin, Inc. (SLRN)
Largest Insider Buys in Sector
SLRN Stock Price History Chart
SLRN Stock Performance
About Acelyrin, Inc.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized …
Insider Activity of Acelyrin, Inc.
Over the last 12 months, insiders at Acelyrin, Inc. have bought $0 and sold $79,195 worth of Acelyrin, Inc. stock.
On average, over the past 5 years, insiders at Acelyrin, Inc. have bought $23.72M and sold $79,195 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,250,000 shares for transaction amount of $22.5M was made by Westlake BioPartners Fund II, L.P. (10 percent owner) on 2023‑05‑09.
List of Insider Buy and Sell Transactions, Acelyrin, Inc.
| 2024-07-17 | Sale | director | 1 <0.0001% | $6.86 | $7 | -28.13% | ||
| 2024-01-02 | Sale | Chief Executive Officer | 10,691 0.0173% | $7.41 | $79,188 | -35.77% | ||
| 2023-05-09 | 10 percent owner | 1.25M 4.929% | $18.00 | $22.5M | -63.02% | |||
| 2023-05-09 | director | 50,000 0.1972% | $18.00 | $900,000 | -63.02% | |||
| 2023-05-09 | director | 15,000 0.0591% | $18.00 | $270,000 | -63.02% | |||
| 2023-05-09 | director | 3,000 0.0118% | $18.00 | $54,000 | -63.02% |